Cited by CrossRef (3)
- . Dasatinib/hydroxycarbamide/ruxolitinib. Reactions Weekly 2019;1750:106
- Yue Zhao, Deepti Reddi, Jenna McCracken, Natasha Iranzad, Cathrine Rehder, Jadee Neff, Endi Wang. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms. 2022;146:710
- Bohyun Kim, Kyu Taek Lee, Young Ahn Yoon, Young-Jin Choi. Clinical significance of myeloproliferative neoplasms with JAK2V617F mutations and major BCR-ABL1 translocations: a literature review with case presentation. Blood Res 2020;55:62